Experimental severe malaria is resolved by targeting newly-identified monocyte subsets using immune-modifying particles combined with artesunate

Current treatment of severe malaria and associated cerebral malaria (CM) and respiratory distress syndromes are directed primarily at the parasite. Targeting the parasite has only partial efficacy in advanced infection, as neurological damage and respiratory distress are due to accumulation of host...

Descripción completa

Detalles Bibliográficos
Autores principales: Niewold, Paula, Cohen, Amy, van Vreden, Caryn, Getts, Daniel R., Grau, Georges E., King, Nicholas J. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292940/
https://www.ncbi.nlm.nih.gov/pubmed/30564748
http://dx.doi.org/10.1038/s42003-018-0216-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292940/
https://www.ncbi.nlm.nih.gov/pubmed/30564748
http://dx.doi.org/10.1038/s42003-018-0216-2

Ejemplares similares